Drug profile · INN
inebilizumab
UPLIZNA
inebilizumab (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AA
Patents linked 0
Pipeline programs 5
News articles 0
Congress events 1
Drug details — inebilizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
inebilizumab (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent.
Key facts
INN inebilizumab
Brand UPLIZNA
Mechanism B-lymphocyte antigen CD19 binding agent
Target B-lymphocyte antigen CD19
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Congress & event coverage
- PresentationEULAR 2026
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is inebilizumab?
inebilizumab (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for inebilizumab?
UPLIZNA is a marketed brand name for inebilizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.